EUVC Live at GoWest | The Outlook for European Capital Sovereignty feat. Olivier Tonneau, Jeppe Høier, Paolo Pio, Fergus Bell and Prashant Agarwal

The two things that make VCs tear their hair out about corporate venture

A CVC expert breaks down the two critical elements that corporate venture capital arms must get right from day one. He explains why having a clear corporate purpose is essential for VC support, and why governance structure - particularly investment committee processes - is where most CVCs fail and frustrate traditional VCs.

The governance mistakes that make VCs tear their hair out

A speaker breaks down the critical governance elements that Corporate VCs must get right to work effectively with traditional VCs. They emphasize the importance of clearly communicating investment committee processes, decision-making structures, and investment strategy to the broader ecosystem.

How corporates can finally speak VC language and win startup partnerships

A speaker outlines a three-step framework for corporates looking to work with startups: act like a VC, learn to communicate in VC terminology about your investment approach and geography, and clearly integrate by being transparent about how you partner with startups. The key insight is that startups are seeking corporates who understand the venture ecosystem rather than traditional corporate approaches.

Living to 200 means nothing if you're miserable the whole time

A discussion about the evolution from simply extending lifespan to focusing on healthspan and ultimately 'joyspan' - the quality of additional years we gain. The speaker critiques extreme longevity pursuits that sacrifice quality of life, questioning whether living longer is worthwhile if it means giving up everything enjoyable.

VC criticizes extreme longevity biohacking: What's the point of living longer miserably?

A VC argues against extreme longevity practices like severe calorie restriction and blood transfusions, advocating instead for 'JoySpan' - extending healthy, enjoyable years rather than just lifespan. They position their investment thesis around supporting founders who focus on quality of life extension rather than obsessive life extension at any cost.

take the Human Genome Project that, in 2003, took billions of dollars and twenty year to decode the first human genome. And now it takes, you know, a few $100 and a few hours to do the same. Right?...

Weightless drugs. Right? I mean, forever we'll be mourning to be lean. Well, now we can just inject ourselves, and that's the case. Right? These are incredible, in a way achievement. But this is just...